

REMARKS

As amended, the application contains claims 1, 6-8, 11, 15-18, 20-22, and 34-36.

In response to the restriction requirement, Applicants provisionally elect with traverse the invention set forth in Group I, Claims 1-8, 11-21, 28, and 34-36, drawn to compounds and pharmaceutical compositions of Formula I, wherein R¹⁰ is phenyl; X is a C₁₋₅ alkylene; A is tropanyl or piperidiny; R¹ is -N-R⁹-Y_m-R³ wherein R⁹ is hydrogen or alkyl, Y is -C(O)-; and R³ is independently selected.


Applicant wishes to point out that X has been defined in the claims and C₁₋₅ alkylene, not as an "alkyl" as suggested by the Examiner. In the claims, the C₁₋₅ alkylene may be substituted by alkyl, but it is not alkyl. Also, Applicant wishes to point out that the election is modified such that R⁹ includes hydrogen, since hydrogen was not named in any of the groupings from the Office.

The claims have been amended in accordance with the election of Group I. Specific examples of the elected Group I compounds are, for example, the compound of Preparation 7 (page 47 of WO 2004/054581, in which A is tropanyl) and the third compound in the table (page 59 of WO 2004/054581, in which A is piperdiny).

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 30 July 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988